| 1 |
Amani B, Amani B. Efficacy and safety of regdanvimab in patients with mild to moderate COVID-19: A rapid review and meta-analysis. Br J Clin Pharmacol 2023;89:1282-90. [PMID: 36717356 DOI: 10.1111/bcp.15676] [Reference Citation Analysis]
|
| 2 |
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis 2023;128:310-7. [PMID: 36229005 DOI: 10.1016/j.ijid.2022.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis 2023:S1473-3099(23)00011-7. [PMID: 36780912 DOI: 10.1016/S1473-3099(23)00011-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Cheng MM, Reyes C, Satram S, Birch H, Gibbons DC, Drysdale M, Bell CF, Suyundikov A, Ding X, Maher MC, Yeh W, Telenti A, Corey L. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA. Infect Dis Ther 2023;12:607-21. [PMID: 36629998 DOI: 10.1007/s40121-022-00755-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol 2023;95:e28441. [PMID: 36576379 DOI: 10.1002/jmv.28441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Rasmussen LD, Lebech AM, Øvrehus A, Poulsen BK, Christensen HR, Nielsen H, Johansen IS, Omland LH, Wiese L, Helleberg M, Storgaard M, Dalager-Pedersen M, Rasmussen TA, Benfield T, Petersen TS, Andersen ÅB, Gram MA, Stegger M, Edslev SM, Obel N. Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark. Br J Clin Pharmacol 2022. [PMID: 36519217 DOI: 10.1111/bcp.15644] [Reference Citation Analysis]
|
| 7 |
Green ACA, Curtis HJ, Higgins R, Nab L, Mahalingasivam V, Smith RM, Mehrkar A, Inglesby P, Drysdale H, DeVito NJ, Croker R, Rentsch CT, Bhaskaran K, Tazare J, Zheng B, Andrews CD, Bacon SCJ, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft LEM, Hulme WJ, Massey J, MacDonald O, Morley J, Morton CE, Park RY, Walker AJ, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas IJ, Evans SJW, Goldacre B, Tomlinson LA, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Med 2023;2:e000276. [PMID: 36936265 DOI: 10.1136/bmjmed-2022-000276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Hicks LK, Vijenthira A. COVID-19 and blood cancer in the vaccination era. Blood 2022;140:2763-5. [PMID: 36580343 DOI: 10.1182/blood.2022018396] [Reference Citation Analysis]
|
| 9 |
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients. BMC Infect Dis 2022;22:818. [DOI: 10.1186/s12879-022-07819-z] [Reference Citation Analysis]
|
| 10 |
Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID-19: A rapid review and meta-analysis. Rev Med Virol 2022;32:e2402. [PMID: 36226323 DOI: 10.1002/rmv.2402] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Iizuka T, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Waragai Y, Kambe T, Kanzaki N, Azuma T, Okamoto H, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Abe W, Tsukada Y, Lee T, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Hamaguchi S, Iseki K. Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate coronavirus disease 2019 during the Omicron variant pandemic.. [DOI: 10.21203/rs.3.rs-2118653/v1] [Reference Citation Analysis]
|
| 12 |
Jalbert JJ, Hussein M, Mastey V, Sanchez RJ, Wang D, Murdock D, Fariñas L, Bussey J, Duart C, Hirshberg B, Weinreich DM, Wei W. Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19. Infect Dis Ther 2022. [PMID: 36181639 DOI: 10.1007/s40121-022-00691-z] [Reference Citation Analysis]
|
| 13 |
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Ginde AA. Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1.. [DOI: 10.1101/2022.09.12.22279866] [Reference Citation Analysis]
|
| 14 |
Arias M, Oliveros H, Lechtig S, Bustos R. Biologics in COVID-19 So Far: Systematic Review. Pharmaceuticals 2022;15:783. [DOI: 10.3390/ph15070783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
